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Background: Four hundred and eighty-eight PiZ alpha-1-antitrypsin deficient patients, who had
joined the UK registry over a 9-year period, were followed in an observational study to deter-
mine mortality. None had received A1AT augmentation therapy.
Methods: Cause of death was confirmed from death certification and medical records. Patients
were censored according to length of time on the program or until they withdrew from the
program.
Results: There were 56 deaths of which 30 were attributed to respiratory causes. Of the re-
maining 26 deaths, 4 were due to complications from lung transplant, 6 due to liver disease
(including 2 post-liver transplant) and the other 16 due to a variety of causes. KaplaneMeier
plots indicated a cumulative hazard for mortality of 18.1% in 9 years, correcting for time of
follow up. When categorised for FEV1 percent-predicted, the group with severe impairment
had increased mortality (pZ<0.001) compared with the mild group and there was a direct
relationship between severity and mortality. The severe group had increased mortality
compared with the mild group when categorised for KCO percent-predicted (p< 0.001), RV/
TLC ratio (p< 0.001) or emphysema score on CT scan (p< 0.001 upper zone). Cox regression
analyses indicated that these relationships remained when corrected for age. There were no
differences in mortality after categorisation for educational level or occupational group.
Conclusion: Mortality in a cohort of A1AT deficient patients (PiZ phenotype) in the UK was 2%
per year and was associated with lung function impairment and emphysema severity on CT
scan, but not social status.
ª 2009 Elsevier Ltd. All rights reserved.t of Respiratory Medicine,
, Wolverhampton, WV10 0QP,
þ44 1902 695725.
.ac.uk (P. Dawkins).
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Alpha-1-antitrypsin deficiency (A1ATD) is classically asso-
ciated with early onset rapidly progressive emphysema.
The prognosis has been considered to be poor with early
mortality in identified cases. Recent data from the.
Mortality in a1-antitrypsin deficiency in the UK 1541American A1ATD register described an overall mortality of
around 3% per year.1 The majority of deaths (72%) were due
to emphysema and around 10% were related to liver
cirrhosis. A previous study from the same database showed
that lower forced expiratory volume in 1 s (FEV1), higher
age, lower educational level, and lung transplant were the
major predictors of mortality.2 Although FEV1 has been
considered the gold standard for the prediction of mortality
in the context of usual chronic obstructive pulmonary
disease (COPD),3e10 our own studies have indicated that the
best predictors of mortality in A1ATD were measures of the
severity of emphysema, namely carbon monoxide gas
transfer corrected for lung volume (KCO) and especially
lung densitometry on computerised tomography (CT)
scan.11
Augmentation therapy is widely available in the USA and
it is generally believed that replenishment of alpha-1-
antitrypsin (A1AT) in deficient subjects should decrease the
progression of emphysema. Indeed comparisons between
subjects receiving and not receiving augmentation therapy
have suggested that lung function decline is greatest in
those with no therapy.2,12,13 Furthermore data also sug-
gested that mortality was seen to be decreased in subjects
receiving augmentation therapy, particularly in those with
an FEV1 predicted of 35e49%.
2 Although these data are
consistent with a beneficial effect of augmentation therapy
on lung function decline, several confounding factors may
have influenced the mortality data including socioeconomic
factors that would influence the affordability of augmen-
tation as well as general health.14e16 In addition, those
receiving augmentation therapy would by necessity have
regular exposure to health care facilities, which in itself
may have a beneficial effect.
Although we had published previous information on
overall mortality in 256 patients for over 4 years,11 we took
the opportunity to describe subsequent mortality and
survival experience in the UK ADAPT (Antitrypsin Deficiency
Assessment and Programme for Treatment) programme for
over 9 years. We explored factors that determined
mortality and survival, which included information on social
status. Unlike the patients on the US registry, none of the
A1ATD patients on our programme had ever received
augmentation therapy, but they all had universal and free
access to health care facilities.Methods
The ADAPT programme assesses A1ATD patients annually in
a single centre. Patients undergo lung function testing
according to the Association of Respiratory Technology and
Physiology (ARTP)/British Thoracic Society (BTS) guide-
lines17 including the measurement of post-bronchodilator
(400 mg salbutamol) flow rates and carbon monoxide uptake
as a measure of gas transfer using the single breath
method. The results are expressed as a percentage pre-
dicted value for the patient’s age, sex and height. The
equipment used was MasterScreen PFT (Jaeger, Germany)
and quality control of equipment and technicians was
according to the American Thoracic Society (ATS)/European
Respiratory Society (ERS) standards.18e20 Patients also have
CT scans for quantitative lung densitometry.21High resolution computerised tomography (HRCT) scans
were performed using a GE Pro speed Scanner (General
Electric Medical Systems, Milwaukee, USA) to obtain 1 mm
slices. The scanner was calibrated weekly for water and air.
A full scan was performed at maximal inspiration (10 mm
intervals) and a limited scan on expiration (30 mm inter-
vals). Two slices were chosen for analysis: the level of the
aortic arch (upper zone) and the level of the inferior
pulmonary vein/right atrial confluence (lower zone). The
data were subjected to density mask analysis, which high-
lighted lung voxels with a density less than 910 Hounsfield
Units (HU). The Voxel Index is the percentage of highlighted
voxels with a lower density than this arbitrarily chosen
threshold, reflecting the proportion of emphysematous
tissue.
A cohort of the first 488 patients with A1ATD, Protease
Inhibitor Z (PiZ) phenotype, who joined the ADAPT program
in Birmingham, UK, over the 9-year period from July 1996 to
July 2005 were studied. None received A1AT augmentation
since it is not licensed for use in the UK.
Causes of death were ascertained from death certifica-
tion, hospital medical records and by contacting the family
practitioners. Deaths primarily related to emphysema, or
an exacerbation of COPD including bronchial infection or
pneumonia leading to respiratory failure, were classified as
respiratory. For the purposes of this study deaths due to
pulmonary embolus were classified as non-respiratory, as
were post-lung-transplant deaths because they were not
directly related to the original emphysema.
Data were collected prospectively as part of a wider
project to study the natural history of progression of the
disease in A1ATD. Since the patients had joined the
program at different times over the 9 years, they were
censored (i.e. removed from the analysis) according to the
length of time they had been on the program, or until they
withdrew from the program (72 cases). In the KaplaneMeier
analyses, by design, the patients were censored on the date
they left the programme and the mortality rate would not
be affected by their withdrawal, with the assumption that
the patients who withdrew were no more or less likely to
die than those who remained in the analysis. KaplaneMeier
plots were made for all-cause mortality. Categorisation
analysis involved splitting these plots into severity groups in
order to perform statistical comparisons. The original
KaplaneMeier plots were categorised into 4 severity groups
according to the lung function, as determined by the FEV1,
KCO and RV/TLC ratio, and CT Voxel Index (1Zmild,
2Zmildemoderate, 3Zmoderateesevere, 4Z severe).
FEV1 was divided according to the GOLD (Global initiative
for chronic Obstructive Lung Disease) criteria, but the other
measures were divided arbitrarily to provide broadly equal
numbers in order to obtain a reasonable spread of patients
across groups. The KaplaneMeier plots were also cat-
egorised for occupational and educational status, using
information from baseline patient questionnaires. The
three educational groups were determined according to the
length of continued education: (1) university or profes-
sional level (finishing age 21 or older), (2) further education
level (finishing age 18 or older), and (3) high school or
secondary education only (finishing age 16 or younger if the
subject left school). The three occupational groups were
determined according to the type of employment based on
1542 P. Dawkins et al.social class categories: (1) professional, managerial or
technical (Social Class I or II), (2) skilled non-manual or
manual (Social Class IIIa or IIIb), (3) partly skilled, unskilled
or long-term unemployed (Social Class IV or V). Finally the
KaplaneMeier curves were categorised for 4 age groups. A
Cox regression analysis of each parameter against mortality
was performed, correcting for age.
Ethical approval was granted by the local research and
ethics committee and all patients gave informed consent
for the investigations.
Analysis
Survival curves were plotted using KaplaneMeier analysis
(SPSS version 12.0). Categorisation for FEV1, KCO, RV/TLC
and education and occupation was performed within this
analysis. Statistical comparison between groups was per-
formed using TaroneeWare pairwise analysis (SPSS version
12.0). A p-value of <0.05 was taken as statistically signifi-
cant. Cox regression analyses were performed for each
parameter in order to correct for age (SPSS version 12.0).
Results
Baseline characteristics of the 488 patients included in the
analysis are illustrated in Table 1. There were 56 deaths in
total in this cohort of patients over the 9-year period.
Median length of follow up was 4.31 years and mean was
4.45 years (range 0.12e8.68 years). Causes of death are
illustrated in the pie chart in Fig. 1. The majority of deaths
were secondary to underlying emphysema (30 out of 56,
54%), which was a lower proportion than that reported from
the US A1ATD registry study (72%). Only 6 (10.7%) died as
a result of liver disease (similar to the 10% reported fromTable 1 Baseline characteristics of the 488 patients included i
Parameter Whole grou
(nZ 488)
Age (years) 50.00 (0.48
Gender (%male) 60.70
Assessment length (years) 4.45 (0.10
FEV1 (%predicted) 55.99 (1.40
KCO (%predicted) 68.61 (1.09
CT scan Voxel Index (upper zone, inspiratory) 31.26 (0.79
CT scan Voxel Index (lower zone, inspiratory) 44.36 (0.93
Incidence of emphysema (%) 78.70
Incidence of chronic bronchitis (%) 39.80
Incidence of reversibility to bronchodilators 55.50
Ex-smoker (%) 67.0
Current smoker (%) 10.5
Pack years 16.43 (0.66
Index cases (%) 88.60
For quantitative data means are shown with standard errors in brack
quantitative variables used ManneWhitney U test because of non-
throughout so t-test was used. Frequencies were tested using Chi-squa
non-survivors. Abbreviation: FEV1Z forced expiratory volume in 1 s;
volume (L); TLCZ total lung capacity (L); CTZ computerised tomogr
production of sputum for at least 3 months of at least 2 consecutivethe US registry). Five died of various malignancies (8.9%
compared with 3% from the US registry); one each of lung,
oesophagus, lymphoma, stomach and brain tumours. The
remainder of the deaths consisted of a miscellaneous group
including cerebrovascular, cardiac, thromboembolic and
other causes including pancreatitis, pulmonary haemor-
rhage and after lung volume reduction surgery.
There had been 72 withdrawals from the program out of
the 488 patients. Of these, 39 were confirmed to be still
alive when contacted by mail, 3 were confirmed as dead
and 30 did not reply or were no longer known at the address
in our database. However, since each patient was censored
at the time of withdrawal from the program (reducing the
denominator in KaplaneMeier analysis by 1), this would not
affect the results of the analysis assuming those who
withdrew were no more or less likely to die than those who
remained. Those who withdrew did have a slightly lower
average baseline FEV1 than those who remained (49.72%
predicted [standard errorþ/ 3.22] versus 57.02% [stan-
dard errorþ/ 1.57], respectively), although this was not
statistically significant. The data for these withdrawals are
summarised in Table 2.
KaplaneMeier analysis shows a cumulative mortality of
18.1% over the 9-year period. Fig. 2a shows the survival
curves categorised for FEV1 percent-predicted, divided into
4 severity groups: >80%, 50e79%, 30e49% and <30%. The
data confirm the stepwise relationship of mortality to the
severity of the airflow obstruction. Fig. 2b shows the survival
curves categorised for KCO, divided into 4 severity groups:
80% predicted, 60e79% predicted, 40e59% predicted and
<40% predicted. The data demonstrate little relationship
between KCO and mortality except for the most severely
affected group (<40% predicted), which shows a significantly
increased mortality compared with the other groups. Fig. 2c
illustrates a significant relationship between worse survivaln the study.
p Survivor
(nZ 432)
Non-survivor
(nZ 56)
Significance
(p-value)
) 49.40 (0.51) 54.70 (1.33) <0.0001
58.90 74.50 0.025
) 4.65 (0.10) 2.85 (0.23) <0.0001
) 58.20 (1.51) 39.51 (3.03) <0.0001
) 69.83 (1.13) 59.37 (3.43) 0.005
) 30.02 (0.82) 41.03 (2.15) <0.0001
) 43.20 (0.98) 53.48 (2.51) 0.002
77.00 91.80 0.017
39.50 41.80 ns (0.740)
55.90 52.70 ns (0.659)
66.7 69.1 ns (0.654)
10.2 12.7 ns (0.631)
) 16.32 (0.70) 17.26 (1.99) ns (0.685)
87.00 100 0.009
ets. For frequency data, percentages are shown. All statistics on
normal distributions, except age which is normally distributed
red test. Significance shown for differences between survivors and
KCOZ gas transfer corrected for alveolar volume; RVZ residual
aphy; nsZ not significant. Chronic bronchitis was defined as daily
years.
Emphysema
30
Liver disease
6
Lung transplant
4
Malignancy
5
CVA
3
Cardiac
3
PE
2
Other
3
Figure 1 Pie chart illustrating the causes of death (56
patients in total). Number of patients who died from each
cause is shown.
Mortality in a1-antitrypsin deficiency in the UK 1543and gas trapping, expressed as residual volume (RV) divided
by total lung capacity (TLC). Fig. 3 shows the survival curves
for extent of emphysema on CT lung densitometry for upper
zone CT scans. Results were similar for lower zone scans
(data not shown). The data indicate a relationship of higher
Voxel Index (signifying worse emphysema) to worse
mortality. Survival curves categorised for educational level
and occupational status indicated no effect on mortality.
There is a significant effect of age on mortality as
expected (Fig. 4). However, when Cox regression analyses
were performed for each parameter against mortality with
correction for age, the relationship of mortality to each
parameter remained strong. This is illustrated in Table 3
which compares the hazard ratio for mortality comparing
the two extreme categorisation groups for each parameter,
with and without correction for age. After age correction
the hazard ratios are slightly reduced, which is reflected asTable 2 Comparative data on patients who withdrew from the
Parameter Withdraw
Age (years) 47.10 (1.
Gender (%male) 56.30
Assessment length (years) 5.19 (0.
FEV1 (%predicted) 49.72 (3.
KCO (%predicted) 66.90 (3.
CT scan Voxel Index (upper zone, inspiratory) 30.28 (2.
CT scan Voxel Index (lower zone, inspiratory) 45.04 (3.
Incidence of emphysema (%) 75.0
Incidence of chronic bronchitis (%) 44.3
Incidence of reversibility to bronchodilators 66.2
Ex-smoker (%) 64.3
Current smoker (%) 17.1
Pack years 16.64 (1.
Index cases (%) 88.5
For quantitative data means are shown with standard errors in brack
quantitative variables used ManneWhitney U test because of non-
throughout so t-test was used. Frequencies were tested using Chi-sq
withdrawn and not withdrawn. Abbreviation: FEV1Z forced expiratory
RVZ residual volume (L); TLCZ total lung capacity (L); CTZ compu
defined as daily production of sputum for at least 3 months of at leaminor changes in the p-values although the relationship of
the parameter to mortality is retained.
Discussion
This observational mortality study has outlined the
mortality rate and causes of death in A1AT deficient
subjects in the UK, and has described the associations of
mortality with lung function measurements and CT scan
emphysema scores. It is unique in that it includes a large
cohort of A1ATD patients studied over a 9-year period, none
of whom had access to or had received A1AT augmentation
therapy, but all of whom had free access to health care
facilities.
Few studies of overall mortality have been reported in
A1ATD. The original studies by Larsson22 noted that life
expectancy was reduced in Swedish subjects compared
with the general population. This reduction was greater in
smokers and males compared with non-smokers and
females. A more recent report from the Swedish registry of
non-smoking PiZ individuals has shown a standardised
mortality ratio of 2.32 compared with the general pop-
ulation, but no increased mortality risk in the individuals
was identified by screening.23
Subsequent mortality rates have been described from
the National Institutes of Health (NIH) registry in the USA.
The original publication in 19982 indicated that there was
a difference between subjects who had ever received
augmentation compared with those who had never received
such therapy. Over a mean 57-month period of follow up
the adjusted relative risk of death was 0.64 (0.43e0.94) in
the 68.9% of patients who had received augmentation
therapy. Whereas this suggested a benefit of augmentation
therapy it was recognised that differences in educational
and social status, which would affect access to the health
care system, may have influenced the outcome. The overallstudy programme and those who remained.
n Not withdrawn Significance (p-value)
21) 50.48 (0.52) 0.01
61.10 ns (0.52)
25) 4.32 (0.10) 0.002
22) 57.02 (1.57) ns (0.12)
04) 68.89 (1.20) ns (0.38)
71) 31.41 (0.98) ns (0.57)
21) 44.25 (1.15) ns (0.68)
79.3 ns (0.44)
39.0 ns (0.40)
52.5 0.02
67.5 ns (0.39)
9.3 0.06
61) 16.40 (0.72) ns (0.71)
88.4 ns (0.98)
ets. For frequency data, percentages are shown. All statistics on
normal distributions, except age which is normally distributed
uared test. Significance shown for differences between patients
volume in 1 s; KCOZ gas transfer corrected for alveolar volume;
terised tomography; nsZ not significant. Chronic bronchitis was
st 2 consecutive years.
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Figure 2 (a) KaplaneMeier survival curve categorised for FEV1 (nZ 472, 56 deaths). Group 1Z80% predicted (nZ 102, 3
deaths). Group 2Z 50e80% predicted (nZ 121, 8 deaths). Group 3Z 30e50% predicted (nZ 149, 22 deaths). Group 4Z<30%
predicted (nZ 100, 23 deaths). Significant differences between groups are shown. (b) KaplaneMeier survival curve categorised for
KCO (nZ 462, 54 deaths). Group 1Z70% predicted (nZ 135, 10 deaths). Group 2Z 50e70% predicted (nZ 157, 17 deaths).
Group 3Z 30e50% predicted (nZ 124, 14 deaths). Group 4Z<30% predicted (nZ 46, 13 deaths). Comparisons of Groups 1e3 are
not statistically significant; differences with Group 4 are shown. (c) KaplaneMeier survival curve categorised for RV/TLC (nZ 465,
50 deaths). Group 1Z RV/TLC< 30% (nZ 114, 5 deaths). Group 2Z RV/TLC 30e40% (nZ 169, 10 deaths). Group 3Z RV/TLC 40e
50% (nZ 123, 20 deaths). Group 4Z RV/TLC 50% (nZ 59, 15 deaths). Significant differences between groups are shown.
1544 P. Dawkins et al.mortality of 18.1% in 9 years for patients not on A1AT
therapy reported in the present study is lower than in the
second study from the NIH registry published more
recently.1 The latter reported a mortality rate of around 3%
per year, although it is not stated what proportion of the
patients received A1AT augmentation. However, the simi-
larity of the mortality rate to that of subjects on augmen-
tation therapy reported in the earlier NIH report2 suggeststhat the majority were on therapy, since the mortality rate
for US subjects who ever received augmentation in that
study was 3.1% per year (106 deaths in 722 subjects) over
the average 57 months of follow up, compared with 2.6% in
those who were never on therapy. Although the mortality
rate for UK patients is similar to that seen for US patients on
augmentation therapy it does not necessarily negate an
effect of this therapy on mortality. The two populations
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Figure 3 KaplaneMeier survival curve categorised for CT
emphysema score (Voxel Index) on upper zone inspiratory
scans (nZ 299, 34 deaths). Group 1Z<15% (nZ 72, 2
deaths). Group 2Z 15e30% (nZ 76, 8 deaths). Group 3Z 30e
45% (nZ 73, 4 deaths). Group 4Z45% (nZ 78, 20 deaths).
Significant differences between groups are shown. In this graph
Group 3 has a lower mortality than Group 2, but the 2 groups
are not significantly different.
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Figure 4 KaplaneMeier survival curve categorised for
age (nZ 488, 56 deaths). Group 1Z<40 (nZ 94, 6 deaths).
Group 2Z 40e50 (nZ 140, 13 deaths). Group 3Z 50e60 pre-
dicted (nZ 168, 18 deaths). Group 4Z60 (nZ 86, 19
deaths). Significant differences between groups are shown.
Mortality in a1-antitrypsin deficiency in the UK 1545may have a different distribution of the various predictors
of mortality, affecting any direct comparison. Indeed the
mean FEV1 predicted in all patients in the current study was
55.99%, compared with 46.72% in the US registry study.
Therefore it remains possible that augmentation may also
have an impact above that of the background health care
system in the UK but direct randomised controlled studies
will be necessary to confirm this.
The relationship of overall mortality to FEV1 in the
present study is, however, in agreement with the US data,
although different FEV1 severity cut-offs were used. We
also divided the FEV1 groups into 5 severities as the US
study1 and the categorisation according to mortality was
retained (data not shown). Therefore the extent of airflow
obstruction appears to be directly proportional to the risk
of death. This is also in agreement with the relationship of
reduced FEV1 and increased mortality in usual COPD.
3e10
There was also an association of gas trapping to mortality,
supporting the relationship of static lung hyperinflation to
mortality found in a recent study in usual COPD.24 In
addition we showed greater mortality only in the severest
group for gas transfer (KCO), suggesting that it is not until
emphysematous disease is significantly advanced that there
is an effect on mortality. An alternative view is supported
by the previous finding that basal emphysema affects FEV1
preferentially and in contrast upper zone emphysema
affects KCO preferentially.25,26 Therefore FEV1 may relate
better to mortality since FEV1 is more affected than KCO in
basal emphysema, which is the most common site affected
in A1ATD. In more severe disease upper zones become
progressively involved leading to a proportionately greatereffect on KCO. Similarly, analyses of emphysema on CT
scans showed that those with the worst emphysema had
significantly increased mortality.
When categorised for educational groupings our data
were at variance with the US registry data in that no
difference was seen for mortality across these groups. This
again is likely to reflect the socialised model of health care
in the UK, where it is possible that even though a much
lower percentage of the country’s gross domestic product is
spent on health than in the USA, there is a more equitable
distribution of resources across socioeconomic groups. This
is also supported by our data categorised for occupational
groupings based on the definitions of social class, although
no equivalent analysis from the US registry is available.
As expected mortality was worse in the group greater
than 60 years of age. However, when Cox regression anal-
yses were performed correcting for age the categorisations
for FEV1, KCO, RV/TLC and CT scan Voxel Index remained
strong, showing that the effect of age did not confound the
analyses to any great extent.
Cause of death was established from hospital records,
certification and records of family practitioners. Since
patients visited the centre from all over the country, it was
impossible to independently verify the cause of death in
many cases, since there is no central registry of death.
However, it can be assumed that the records of family
practitioners are accurate since either they have
completed the death certificate themselves if the patient
died outside of hospital, or they have been in receipt of
details of death certification from the hospital in which the
patient died. The major causes of death (30 out of 56,
53.6%) relate directly to emphysema. If deaths related to
lung transplant were counted as respiratory deaths this
would be 60.7%, still lower than that reported due to
Table 3 Hazard ratios for mortality (Exp B) for parameters before and after correction for age, comparing Group 1 and Group
4 for each parameter on the corresponding KaplaneMaier graph (Figs. 3 and 4).
Parameter Hazard ratio
(Exp B)
Lower 95th CI Upper 95th CI Significance
(p-value)
FEV1 0.125 0.038 0.417 0.001
FEV1 (age corrected) 0.134 0.04 0.447 0.001
KCO 0.244 0.107 0.557 0.001
KCO (age corrected) 0.297 0.129 0.683 0.004
RV/TLC 0.170 0.062 0.468 0.001
RV/TLC (age corrected) 0.230 0.083 0.640 0.005
CT Voxel Index 0.111 0.026 0.473 0.003
CT Voxel Index (age corrected) 0.137 0.032 0.589 0.008
A hazard ratio of <1 means there is an increased risk of mortality in Group 4 compared with Group 1. After age correction the hazard
ratios move a little towards 1 and the p-values rise slightly, but the relationship of the parameter to mortality still holds for each
parameter. FEV1Z forced expiratory volume in 1 s; KCOZ gas transfer corrected for alveolar volume; RVZ residual volume (L);
TLCZ total lung capacity (L); CTZ computerised tomography. For CT Voxel Index upper zone inspiratory scans are shown.
1546 P. Dawkins et al.emphysema in the NIH registry.1 This is in contrast to
a recent study of mortality in usual COPD27 where only 35%
of the deaths were ‘‘respiratory’’ (excluding lung cancer).
However, this latter study showed a much higher proportion
of cardiovascular deaths (27%) than our A1ATD patients
(5.4%), probably reflecting the younger age group and
hence lack of comorbidity in our patients for equivalent
severity of COPD. In addition there was also a lower pack
year history in the especially susceptible patients in the
present study, despite similar impairment in FEV1, which
may also have had an effect on comorbidities.
Some limitations in this study have been discussed.
Comparisons with patients in the US are limited by the
different case mix of patients between the A1AT deficiency
registries of the two countries, the UK patients on average
having milder disease as measured by FEV1. Also there are
so many variables in 2 quite different health care systems
that it is difficult to identify potentially important aspects
that may affect mortality. The KaplaneMeier analyses
correct for patients withdrawing from follow up by
censoring at the time they leave, but it is possible that
some patients who withdrew had more physiological
impairment (though not significantly different as a group)
than those who remained, which could influence mortality.
Thirty of the withdrawals could not be traced and the
assumption had to be made that these had the same like-
lihood of survival as the other subjects in the study. Finally,
there could be possible biases in the recording of death
certification data, since most deaths occurred outside our
institution so medical notes could not always be verified
independently. However, although this could influence the
cause of death it would not alter the overall mortality rate.
In summary we have found that mortality in UK of A1ATD
patients is 18.1% over 9 years (2% per year). This is influ-
enced by the baseline FEV1, RV/TLC, KCO and the extent of
emphysema on CT scan, but not social class or educational
level. The mortality rate is similar to that seen in the USA
for patients on augmentation therapy, however differences
in the populations studied in the two countries indicate
that the results of randomised controlled trials of thistreatment on mortality will be necessary to determine the
true effect.
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